Repros Therapeutics Downgraded to “Buy” at Ascendiant Capital Markets (RPRX)
Repros Therapeutics (NASDAQ:RPRX) was downgraded by Ascendiant Capital Markets from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday, TheFlyOnTheWall.com reports. They currently have a $25.00 price target on the stock. Ascendiant Capital Markets’ target price points to a potential upside of 46.03% from the company’s current price.
The analysts wrote, “Yesterday, the company announced that the FDA communicated to them that it has some concerns about the adequacy of including patients enrolled at one clinical site in Miami in the ZA-301 Phase III clinical study that evaluated the safety and efficacy of Androxal for the treatment of low testosterone. As a result, the company has been instructed by the FDA to request a meeting to discuss the issue. Repros expects that this meeting will likely be scheduled some time in December.”
Several other analysts have also recently commented on the stock. Analysts at Ladenburg Thalmann raised their price target on shares of Repros Therapeutics from $25.00 to $35.00 in a research note to investors on Thursday, September 19th. They now have a “buy” rating on the stock. Separately, analysts at Bank of America Corp. reiterated a “buy” rating on shares of Repros Therapeutics in a research note to investors on Wednesday, September 18th. They now have a $35.00 price target on the stock, up previously from $25.00. Finally, analysts at Brean Capital reiterated a “buy” rating on shares of Repros Therapeutics in a research note to investors on Tuesday, September 17th. Six analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $31.40.
Repros Therapeutics (NASDAQ:RPRX) traded up 5.84% during mid-day trading on Wednesday, hitting $18.12. 453,569 shares of the company’s stock traded hands. Repros Therapeutics has a one year low of $8.42 and a one year high of $24.42. The stock’s 50-day moving average is $20.4 and its 200-day moving average is $17.45. The company’s market cap is $416.8 million.
Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.40) by $0.02. Analysts expect that Repros Therapeutics will post $-1.40 EPS for the current fiscal year.
Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.